RxDoctor Payments DataLook up a doctor →

Jose Diaz, MD

Pulmonary Disease · Leesburg, FLNPI 1659318608

Payments from drug & device makers

$11,201,290in general payments, 2019–2025

Across 2,515 payments — averaging $4453.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$6.1M
  • Astrazeneca UK Limited$1.3M
  • GSK$1.2M
  • Bavarian Nordic A/s$787K
  • Boehringer Ingelheim$471K
  • Merck$212K
  • plus $1.1M from 54 others
$2,014in research payments, 2019–2025

Across 14 payments — averaging $143.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.569$6,113,705
Astrazeneca UK Limited5$1,289,293
GSK366$1,216,340
Bavarian Nordic A/s149$787,088
Boehringer Ingelheim145$470,686
Merck11$211,919
Medtronic23$187,976
AstraZeneca(2 entities)107$166,574
Genentech, Inc.163$166,132
Insmed, Inc.209$128,970
E.r. Squibb & Sons, L.L.C.6$69,143
Sanofi Pasteur Inc.18$46,632
Mylan Specialty L.p.27$45,287
Chugai Pharmaceutical Co., Ltd.10$44,843
Shionogi Inc14$42,157
Hoffmann-la Roche Limited8$39,835
Teva Pharmaceuticals USA, Inc.12$35,415
Roche Products Limited7$29,448
Grifols Therapeutics LLC4$18,285
Boehringer Ingelheim International GmbH101$18,109
Regeneron1$17,500
F. Hoffmann-la Roche AG6$12,218
Actelion Pharmaceuticals, Ltd6$7,411
Chiesi USA, Inc.5$6,580
Pulmonx Corporation27$6,193
Genentech USA, Inc.14$4,933
Novartis3$4,339
Sanofi40$2,421
Viiv Healthcare Company1$1,600
Regeneron Healthcare Solutions, Inc.43$1,387
Actelion Pharmaceuticals US, Inc.52$1,359
Mallinckrodt Hospital Products Inc.49$1,054
Takeda Pharmaceuticals U.S.A., Inc.37$941
Philips North America LLC47$845
Grifols USA, LLC41$842
Electromed, Inc.52$575
United Therapeutics Corporation12$391
Verona Pharma, Inc.28$381
Viatris Specialty LLC15$277
Abbott1$270
Inari Medical, Inc.2$226
Vanda Pharmaceuticals Inc.6$166
Fisher & Paykel Healthcare Inc3$134
Gilead6$130
Circassia Inc.9$123
Amgen5$109
Baxter Healthcare5$100
Sanofi-aventis U.S. LLC1$99
Inogen, Inc.6$97
Covis Pharma GmbH4$94
Bayer3$55
Cook Medical LLC2$52
Vifor Pharma, Inc.2$50
CSL Behring2$45
ZOLL Respicardia, Inc.2$40
Biogen2$39
3b Medical, Inc.1$35
Lilly USA, LLC2$34
ANI Pharmaceuticals, Inc.1$34
Resmed Corp1$31

How this compares

$11,201,290 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida →

Medicare billing

Part B allowed, 2024
$554,999
Medicare patients
1,616
Services billed
8,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Leesburg

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →